Recently our Dean of Libraries, Gali Halevi, MLS, PhD, was approached by School leadership to help develop a method to better identify top scientists and researchers while demystifying the recruitment of diverse faculty. With that in mind, Dr. Halevi, has created a methodology using publications and the Plum Analytics platform as the basis for identifying diverse faculty candidates for the School.
We are excited to share her methodology with our community and beyond, as we hope that this methodology can be shared and utilized by other institutions to help in own recruitment efforts with recruiting diverse faculty, scientists, and researchers.
Each month Levy Library showcases the achievements of Mount Sinai faculty and researchers by highlighting an article and its altmetrics. Altmetrics are alternative measures of impact that capture non-traditional data like abstract views, article downloads, and social media activity. Our altmetrics data is provided by the PlumX platform.
This month we highlight A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. This article was written in part by Kris M White, PhD, Lisa Miorin PhD, Mehdi Bouhaddou, Nevan Krogan PhD, and Adolfo Garcia-Sastre, PhD.
ABSTRACT
A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2. There are no antiviral drugs with proven clinical efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that physically associated with each of the SARS-CoV-2 proteins using affinity-purification mass spectrometry, identifying 332 high-confidence protein–protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors. Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.
View the PlumX article profile